ArticlePharmacoEconomics2010
Access with evidence development: the US experience.
Article in PharmacoEconomics, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 54 citations in OpenAlex.
- Healthcare Systems across Europe and the US: The Managed Entry Agreements Experience.Healthcare (Basel, Switzerland) · 2023Article
- How Managed Entry Agreements can improve allocation in the public health system: a mechanism design approach.The European journal of health economics : HEPAC : health economics in prevention and care · 2021Article
- A proposed approach to accelerate evidence generation for genomic-based technologies in the context of a learning health system.Genetics in medicine : official journal of the American College of Medical Genetics · 2018Review
- Adaptive Biomedical Innovation: Evolving Our Global System to Sustainably and Safely Bring New Medicines to Patients in Need.Clinical pharmacology and therapeutics · 2016Article
- Reference pricing with evidence development: a way forward for proton therapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2014Article
- Politics and its intersection with coverage with evidence development: a qualitative analysis from expert interviews.BMC health services research · 2013Article
- Building the evidence base for decision making in cancer genomic medicine using comparative effectiveness research.Genetics in medicine : official journal of the American College of Medical Genetics · 2012Review
- How comparative effectiveness research can help advance 'personalized medicine' in cancer treatment.Health affairs (Project Hope) · 2011Article
- Overhauling the reimbursement system for molecular diagnostics.Nature biotechnology · 2011Article
- What is the value of oncology medicines?Nature biotechnology · 2010Article
- Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers.BMC health services research · 2010Review
- Single technology appraisal at the UK National Institute for Health and clinical excellence: a source of evidence and analysis for decision making internationally.PharmacoEconomics · 2010Article
- Principles of design of access with evidence development approaches: a consensus statement from the Banff Summit.PharmacoEconomics · 2010Article
- We know accurately only when we know little.PharmacoEconomics · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The concept of access with evidence development (AED), also known as 'coverage with evidence development' in the Medicare programme, has long been discussed as a policy option for ensuring more appropriate use of new technologies in the US. This article provides a comprehensive overview of more than 10 years of US experience with AED, both in the public and private healthcare sectors. Beginning with a discussion of the successes of private plans' conditional coverage for high-density chemotherapy for autologous bone marrow transplants for metastatic breast cancer and Medicare's conditional coverage of lung-volume-reduction surgery in the 1990s, the article moves on to describe how Medicare worked to codify AED as one of its coverage policy options in the early part of this decade. More recent private and public sector initiatives are also discussed, including an overview of barriers to implementing AED. Despite the complexity of political, financial and ethical issues faced in implementation, AED is now a permanent fixture of US coverage policy. Future initiatives within the Medicare programme and with private payers in the US are much more likely to succeed by relying upon the simple but consequential principles laid out at a Summit convened in Banff, Alberta, Canada in 2009 and presented in another article in this issue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.